Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, Nielsen OW, Haugaard SB, Sajadieh A

Diabetes care19 Oct 2016Cited by 76 (Europe PMC)

PMID27797930DOI10.2337/dc16-1580PepBankPUB-27797930

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease on metformin, liraglutide decreased SDNN versus placebo.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide lowered heart rate variability compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseHeart rate variability (SDNN)
Study
n = 27
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
SDNN difference
−33.9 ms
liraglutide vs placebo
Source sentences
Summary
Compared with placebo, liraglutide decreased SDNN in 27 subjects (-33.9 ms; P < 0.001, paired analysis)
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793001
02HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease on metformin, liraglutide decreased RMSSD versus placebo.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide lowered a heart rate variability measure compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseRMSSD
Study
n = 27
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
RMSSD difference
−0.3 log-ms
liraglutide vs placebo
Source sentences
Summary
Compared with placebo, liraglutide decreased SDNN in 27 subjects (-33.9 ms; P < 0.001, paired analysis); decreased RMSSD (-0.3 log-ms; P = 0.025)
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793002
03HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease on metformin, liraglutide increased mean heart rate versus placebo.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide raised the average heart rate compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseMean heart rate
Study
n = 27
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Mean heart rate difference
8.1 beats/min
liraglutide vs placebo
Source sentences
Summary
and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026).
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793003
04HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease on metformin, the daytime heart rate rise of 5.7 with liraglutide versus placebo was not significant (P = 0.083).
In plain wordsIn overweight people with diabetes and heart disease, the daytime heart rate rise with liraglutide was not statistically significant versus placebo.
Peptide
Liraglutide
Outcome
No significant changeDaytime heart rate
Study
n = 27
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Daytime heart rate difference
5.7
liraglutide vs placebo
Source sentences
Summary
daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026).
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793004
05HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease on metformin, liraglutide increased nighttime heart rate versus placebo.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide raised the night-time heart rate compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseNighttime heart rate
Study
n = 27
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Nighttime heart rate difference
6.3
liraglutide vs placebo
Source sentences
Summary
and nighttime HR (6.3; P = 0.026).
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793005
06HumanRandomized controlled trialSafety outcome
In a multivariable analysis, the liraglutide-related decrease in SDNN stayed significant after adjustment for metabolic and heart rate changes.
In plain wordsIn overweight people with diabetes and heart disease, the drop in heart rate variability with liraglutide stayed after adjusting for metabolic and heart rate changes.
Peptide
Liraglutide
Outcome
DecreaseSDNN after adjustment for metabolic and heart rate changes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793006
07HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease, liraglutide reduced HF power versus placebo.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide lowered a measure of parasympathetic heart activity compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseHigh-frequency (HF) power
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
HF power change
−0.7 log-ms2
liraglutide vs placebo
Source sentences
Summary
Liraglutide reduced HF power (-0.7 log-ms²; P = 0.026) without any change in LF/HF ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793007
08HumanRandomized controlled trialSafety outcome
In overweight patients with type 2 diabetes and stable coronary artery disease, liraglutide did not change the LF/HF ratio.
In plain wordsIn overweight people with diabetes and heart disease, liraglutide did not change the balance ratio of low and high frequency heart signals.
Peptide
Liraglutide
Outcome
No significant changeLF/HF ratio
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
without any change in LF/HF ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).
Summary · context
Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study.
Report a problemFND-2779793008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01595789

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Haugaard, Steen Bendix, M.D., DMScn = 41May 2012 to Jul 2015

Coronary Artery Disease · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.